MedTech Terms
    The authoritative reference
    All terms

    Off-Label Use

    Use of a device for an indication not in its cleared/approved labeling.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Physicians may legally use a cleared device off-label in the practice of medicine. Manufacturers may not promote off-label use; doing so risks FDA enforcement and False Claims Act exposure when federal payment is involved.
    What the regulation says
    The FDA recognizes that off-label use is often an important part of medical practice, as outlined in FDA guidance documents on unapproved uses of approved drugs and medical devices. However, manufacturers are strictly prohibited from promoting off-label uses of their MedTech products, a principle reinforced by Section 502(a) of the Food, Drug, and Cosmetic Act concerning misbranding. The European Medical Device Regulation (EU MDR) also implicitly addresses off-label use by requiring devices to be safe and perform as intended by the manufacturer within their "intended purpose," as defined in Article 2, point 12.

    What this means in practice

    Common in cardiology, orthopedics, and pediatrics where on-label populations are narrow. Manufacturers may share scientific information consistent with FDA guidance on responsive communications.

    Examples

    • A surgeon uses an FDA-cleared surgical stapler, approved for abdominal procedures, in a novel cardiothoracic application based on their clinical judgment and peer-reviewed literature.
    • A medical device company provides a healthcare professional with a reprint of a peer-reviewed article discussing a potential off-label use of their device, in response to an unsolicited request for information.
    • A physician prescribes a drug-eluting stent, approved for coronary arteries, for use in peripheral artery disease, citing scientific evidence from a professional medical society guideline.
    Common pitfalls
    • •Manufacturers can be penalized under the False Claims Act if off-label promotion leads to federal healthcare program reimbursement for non-covered uses.
    • •Assuming that the absence of a specific contraindication implies regulatory approval for an off-label application is a common pitfall.
    • •Failing to establish clear internal policies and training regarding permissible and impermissible communications about off-label use can lead to compliance breaches.
    • •Ignoring the ethical implications and potential patient harm associated with off-label use without sufficient scientific evidence can lead to serious consequences.
    • •Misinterpreting FDA guidance on firm-sponsored scientific and medical exchanges regarding unapproved uses can inadvertently lead to promotional activities.

    Frequently asked questions

    Yes, manufacturers can generally respond to unsolicited requests for information about off-label uses from healthcare professionals, provided the information is truthful, balanced, evidence-based, and non-promotional. This is often covered under specific FDA guidance for unsolicited requests.
    Grouped by theme

    Mentioned in recent activity

    1 entry

    Latest in MedTech

    View all

    Recent regulatory actions, publications, and trials matched to this term. Updated daily.

    Primary references

    2 sources
    Link health: 2 verified· last checked 2026-06-20
    AdvaMed·1AHRMM·1
    1. 1
      AdvaMed Code of Ethics
      Verified
      AdvaMedadvamed.org
    2. 2
      AHRMM - Healthcare Supply Chain
      Verified
      AHRMMahrmm.org

    Inline markers like [1] jump to the matching reference above.